COMMUNIQUÉS West-GlobeNewswire

ACTG Announces Behavioral Health and Implementation Study to Optimize Long-Acting HIV Treatment among People who have Struggled to Maintain HIV Suppression
17/07/2026
CHAPEL HILL, N.C., July 17, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of A5432, a study assessing factors that may affect [...]
Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives
17/07/2026
RUTHERFORD, N.J. and SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), together with its operating business Lōkahi Therapeutics™ ("Lōkahi") , a clinical-stage [...]
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
17/07/2026
Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/mL in 50 mL vial, significantly expands Amneal’s injectable contrast portfolio Portfolio now positioned to address the [...]
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
17/07/2026
Houston, Texas and Tuebingen, Germany, July 17, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell [...]
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology
17/07/2026
Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies. TAIPEI, TAIWAN, July 17, 2026 ( [...]
Sienna Announces Long-Term Care Redevelopment in Greater Toronto Area
17/07/2026
MARKHAM, Ontario, July 17, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA) announced today that it will proceed with its next redevelopment project in the Greater Toronto [...]
Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program
17/07/2026
TORONTO, July 17, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has engaged a U.S.-based laboratory specializing in bioengineering to accelerate the Company [...]
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
17/07/2026
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple [...]
Enovis to Host Second Quarter 2026 Results Conference Call on August 6th
17/07/2026
Dallas, TX, July 17, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to [...]
Damora Announces Redomestication from Delaware to Cayman Islands
17/07/2026
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today [...]
SS Innovations To Showcase the SSi Mantra Surgical Robotic System at SRS 2026
17/07/2026
Company’s advanced surgical robotic system will be on display, spotlighted in multiple breakout sessions, and featured in a kidney telesurgery to be broadcast live at the premier industry event FORT LAUDERDALE, Fla., [...]
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
17/07/2026
Vancouver, Canada, July 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Alcohol Use Disorder [...]
BrewDog and Tilray Brands Unlock £1 Million Bar Tab for Football Fans Across England, Scotland and Ireland
17/07/2026
BrewDog and Tilray are keeping football’s biggest celebration alive by unlocking the £1 million bar tab at participating pubs 1 beginning July 20 because great football deserves celebrating, no matter who lifts the [...]
Orion Group Half-Year Financial Report January–June 2026
17/07/2026
ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2026 17 JULY 2026 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2026 April–June 2026 Highlights Net sales totalled EUR 521.6 (April–June 2025: 416.5) [...]
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
17/07/2026
Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response Data will also offer insight into the vaccine’s effect [...]
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/07/2026
SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients [...]
Orion Corporation’s financial reporting and Annual General Meeting in 2027
17/07/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 17 JULY 2026 at 10.30 EEST Orion Corporation’s financial reporting and Annual General Meeting in 2027 Orion Corporation will publish its Financial Statement [...]
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline
17/07/2026
Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist Dimerix Limited (ASX: DXB) Mission will receive up to US$292 million in [...]
European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
17/07/2026
Not intended for UK and US audiences JASCAYD® (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the European Union, delivering a novel mechanism of action with antifibrotic and immunomodulatory [...]

Pages